Residency · Residency · Otolaryngology
Pediatric Hearing Loss: Screening, Diagnosis, and Intervention
Overview
Hearing loss affects 1-3 per 1,000 newborns and is the most common congenital sensory deficit. Early identification through universal newborn hearing screening (UNHS) and timely intervention are critical for speech, language, and cognitive development. The otolaryngologist plays a central role in etiologic evaluation, medical and surgical management, and coordination of audiologic rehabilitation including hearing aids and cochlear implants.
Universal Newborn Hearing Screening (UNHS)
Rationale
Critical period for auditory-linguistic development: birth to 3 years. Children identified and intervened by 6 months of age have significantly better language outcomes than those identified later (Yoshinaga-Itano landmark study). JCIH (Joint Committee on Infant Hearing) recommends 1-3-6 benchmarks: screen by 1 month, diagnose by 3 months, intervene by 6 months.
Screening Methods
Otoacoustic emissions (OAE): measures sounds generated by the outer hair cells of the cochlea; screens cochlear function; does not detect auditory neuropathy spectrum disorder (ANSD). Automated auditory brainstem response (AABR): measures neural response to sound; screens the cochlea and auditory nerve; detects ANSD. NICU infants should be screened with AABR (higher incidence of ANSD). Refer rate: 2-10% fail initial screen; 50% of these pass on rescreen.
Follow-Up for Failed Screen
Rescreen within 1 month. If rescreen fails: diagnostic ABR by 3 months of age. Loss to follow-up is a significant problem (30-50% of referred infants do not complete diagnostic testing).
Etiologic Evaluation
Genetic Causes (50-60% of Congenital SNHL)
GJB2 mutations (Connexin 26): most common cause of non-syndromic autosomal recessive SNHL; accounts for 30-50% of genetic cases; mutations in the gap junction protein. GJB6 (Connexin 30): less common; associated with GJB2 mutations. Genetic testing panel: comprehensive next-generation sequencing panels testing >100 deafness genes are now standard. SLC26A4 (Pendred syndrome): sensorineural hearing loss + enlarged vestibular aqueduct (EVA) + thyroid goiter; autosomal recessive. Usher syndrome: SNHL + retinitis pigmentosa; most common syndromic cause of combined hearing-vision loss. Waardenburg syndrome: SNHL + pigmentation abnormalities (white forelock, heterochromia); autosomal dominant. Branchio-oto-renal (BOR) syndrome: hearing loss + branchial cleft anomalies + renal anomalies. Treacher Collins, CHARGE, Down syndrome: syndromic hearing loss with other associated features.
Acquired/Environmental Causes (25-30%)
Congenital CMV: most common non-genetic cause; may cause progressive or late-onset SNHL; detected by urine CMV PCR within 3 weeks of birth. Ototoxic medications: aminoglycosides, loop diuretics (NICU exposure). Hyperbilirubinemia: risk factor for ANSD. Meningitis: bacterial meningitis causes SNHL in 10-30%; cochlear ossification may limit CI candidacy. Prematurity: NICU stay, hypoxia, noise exposure.
Imaging
MRI (temporal bones and brain): preferred initial imaging; evaluates cochlear nerve, inner ear malformations, brain abnormalities. CT temporal bones: evaluates bony anatomy (cochlear morphology, vestibular aqueduct, ossicles, facial nerve course). Common findings: Enlarged vestibular aqueduct (EVA): >1.5 mm at midpoint; associated with SLC26A4 mutations. Cochlear nerve deficiency (absent or hypoplastic cochlear nerve): seen on MRI; impacts CI candidacy. Mondini malformation (incomplete partition type II): 1.5 cochlear turns instead of 2.5. Common cavity: single cavity without modiolus or cochlear turns. Cochlear aplasia: absent cochlea.
Additional Workup
Ophthalmologic evaluation: Usher syndrome screening. ECG: prolonged QT (Jervell and Lange-Nielsen syndrome). Renal ultrasound: BOR syndrome, Alport syndrome. Thyroid function: Pendred syndrome. Congenital CMV testing (urine PCR within first 3 weeks of life; dried blood spot retrospectively).
Classification of Hearing Loss
Type
Conductive: outer or middle ear pathology (OME, ossicular fixation, aural atresia). Sensorineural: inner ear or auditory nerve (most congenital hearing loss). Mixed: combination. Auditory neuropathy spectrum disorder (ANSD): present OAE, absent or abnormal ABR; cochlear function normal, neural transmission impaired.
Degree
| Grade | Threshold (dB HL) |
|---|---|
| Normal | ≤20 |
| Mild | 21-40 |
| Moderate | 41-55 |
| Moderately severe | 56-70 |
| Severe | 71-90 |
| Profound | >90 |
Normal: <= 20 dB HL. Mild: 21-40 dB HL. Moderate: 41-55 dB HL. Moderately severe: 56-70 dB HL. Severe: 71-90 dB HL. Profound: >90 dB HL.
Intervention
Hearing Aids
First-line for mild to severe SNHL, Fit within 1 month of diagnosis (JCIH 1-3-6 goals). Behind-the-ear (BTE): standard for pediatric patients; adjustable as the child grows. Amplification tailored to the audiogram using real-ear measurements. FM systems for classroom use. Bone conduction hearing devices (BCHD): for conductive or mixed hearing loss when conventional hearing aids are not suitable (aural atresia, chronic ear disease). Softband BCHD for infants/toddlers. Osseointegrated implant (BAHA/Ponto) at age >= 5 years.
Cochlear Implants
Indicated for bilateral severe-to-profound SNHL with limited benefit from hearing aids. FDA approved: age >= 9 months (unilateral), age >= 12 months in many programs. Expanding criteria: children with single-sided deafness, auditory neuropathy, and residual hearing (hybrid/EAS). Bilateral simultaneous or sequential implantation preferred for binaural hearing. Post-meningitic children: urgent imaging and consideration for early implantation before cochlear ossification. Speech perception outcomes: 80-90% achieve open-set speech perception with early implantation and consistent therapy. Requires intensive auditory-verbal therapy or auditory-oral education.
Auditory Neuropathy Spectrum Disorder (ANSD)
Present OAE with absent/abnormal ABR, May fluctuate; some children develop normal hearing. Hearing aids: trial first; may not provide adequate benefit. Cochlear implants: effective in many ANSD children (bypasses the neural desynchrony). Etiologies: premature birth, hyperbilirubinemia, genetic (OTOF mutations), neonatal hypoxia.
Early Intervention Services
Individualized Family Service Plan (IFSP) by 6 months, Speech-language therapy. Communication modality: spoken language, sign language, or combination (family choice). Parent education and support.
<image>Universal newborn hearing screening and diagnostic pathway. Flowchart starting with birth, OAE or AABR screening by 1 month. Pass result leads to routine monitoring with risk factor surveillance. Fail result leads to rescreen, then diagnostic ABR by 3 months if rescreen fails. Diagnostic ABR results branch to normal hearing (monitor if risk factors), conductive hearing loss (ENT evaluation, OME management), sensorineural hearing loss (etiologic workup: genetics, CMV, imaging, ophthalmology), or ANSD (monitor, hearing aid trial, consider CI). Intervention by 6 months: hearing aids, early intervention services, and CI evaluation if severe-profound. JCIH 1-3-6 benchmarks are highlighted at each stage.</image>
<image>Inner ear imaging findings in congenital hearing loss. Six panels showing CT and MRI images. Panel A: Normal cochlea with 2.5 turns and normal vestibular aqueduct on CT. Panel B: Enlarged vestibular aqueduct (EVA) on CT with measurement showing >1.5 mm at midpoint. Panel C: Mondini malformation (incomplete partition type II) on CT showing 1.5 cochlear turns with dilated vestibule. Panel D: Common cavity on CT showing a single round chamber without internal architecture. Panel E: MRI showing normal cochlear nerve in the internal auditory canal (four distinct nerves). Panel F: MRI showing absent cochlear nerve with only three nerves visible in the IAC. Each panel is labeled with the diagnosis and clinical significance.</image>
<image>Hearing rehabilitation options for pediatric hearing loss arranged by severity. Horizontal axis shows degree of hearing loss from mild to profound. For each severity level, the recommended device is illustrated: mild-moderate shows behind-the-ear hearing aid on a child's ear; moderate-severe shows a more powerful BTE hearing aid with earmold; severe-profound shows a cochlear implant (external processor and internal electrode array within the cochlea). A separate row shows bone conduction devices: softband BCHD for infants and osseointegrated implant (BAHA) for children >= 5 years, indicated for conductive or mixed hearing loss. Age-appropriate audiometric testing methods are listed below each severity category.</image>
Clinical Pearls
The JCIH 1-3-6 benchmarks (screen by 1 month, diagnose by 3 months, intervene by 6 months) are critical; delays in identification and intervention directly impact speech and language outcomes. GJB2 (Connexin 26) mutations are the most common cause of non-syndromic congenital SNHL; genetic testing should be offered to all families with a child diagnosed with sensorineural hearing loss. Congenital CMV is the most common non-genetic cause of SNHL and can cause progressive or late-onset hearing loss; diagnosis requires urine CMV PCR within the first 3 weeks of life. Cochlear nerve deficiency on MRI is a critical finding that impacts cochlear implant candidacy; if the nerve is absent, an auditory brainstem implant may be considered instead. Post-meningitic hearing loss can progress rapidly due to cochlear ossification; urgent imaging and early cochlear implantation are essential to ensure electrode insertion before the cochlea ossifies. NICU infants should be screened with AABR rather than OAE because ANSD is more prevalent in this population and would be missed by OAE alone.
References
- Joint Committee on Infant Hearing. "Year 2019 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs." J Early Hear Detect Interv. 2019;4(2):1-44.
- Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. "Language of early- and later-identified children with hearing loss." Pediatrics. 1998;102(5):1161-1171.
- Smith RJH, Bale JF, White KR. "Sensorineural hearing loss in children." Lancet. 2005;365(9462):879-890.
- Lieu JEC, Kenna M, Anne S, Davidson L. "Hearing loss in children: a review." JAMA. 2020;324(21):2195-2205.
